<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35926726</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1995-820X</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Virologica Sinica</Title><ISOAbbreviation>Virol Sin</ISOAbbreviation></Journal><ArticleTitle>Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infants.</ArticleTitle><Pagination><StartPage>724</StartPage><EndPage>730</EndPage><MedlinePgn>724-730</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virs.2022.07.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1995-820X(22)00135-3</ELocationID><Abstract><AbstractText>A randomized, double-blind, placebo-controlled multicenter trial was conducted in healthy Chinese infants to assess the efficacy and safety of a hexavalent live human-bovine reassortant rotavirus vaccine (HRV) against rotavirus gastroenteritis (RVGE). A total of 6400 participants aged 6-12 weeks were enrolled and randomly assigned to either HRV (n&#xa0;&#x200b;=&#xa0;&#x200b;3200) or placebo (n&#xa0;&#x200b;=&#xa0;&#x200b;3200) group. All the subjects received three oral doses of vaccine four weeks apart. The vaccine efficacy (VE) against RVGE caused by rotavirus serotypes contained in HRV was evaluated from 14 days after three doses of administration up until the end of the second rotavirus season. VE against severe RVGE, VE against RVGE hospitalization caused by serotypes contained in HRV, and VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were also investigated. All adverse events (AEs) were collected for 30 days after each dose. Serious AEs (SAEs) and intussusception cases were collected during the entire study. Our data showed that VE against RVGE caused by serotypes contained in HRV was 69.21% (95%CI: 53.31-79.69). VE against severe RVGE and RVGE hospitalization caused by serotypes contained in HRV were 91.36% (95%CI: 78.45-96.53) and 89.21% (95%CI: 64.51-96.72) respectively. VE against RVGE, severe RVGE, and RVGE hospitalization caused by natural infection of any serotype of rotavirus were 62.88% (95%CI: 49.11-72.92), 85.51% (95%CI: 72.74-92.30) and 83.68% (95%CI: 61.34-93.11). Incidences of AEs from the first dose to one month post the third dose in HRV and placebo groups were comparable. There was no significant difference in incidences of SAEs in HRV and placebo groups. This study shows that this hexavalent reassortant rotavirus vaccine is an effective, well-tolerated, and safe vaccine for Chinese infants.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Publishing services by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hebei Center for Disease Control and Prevention, Shijiazhuang, 050021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qingliang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Huakun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Zhaojun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, 530028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fangjun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hunan Center for Disease Control and Prevention, Changsha, 410005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Qingchuan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hebei Center for Disease Control and Prevention, Shijiazhuang, 050021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Teng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, 530028, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xiaosong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Hunan Center for Disease Control and Prevention, Changsha, 410005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jiamei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Haisong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Zhengding County Center for Disease Control and Prevention, Shijiazhuang, 050800, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yueyue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenzhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yingping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiuwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Jialiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Biao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Zhejiang Center for Disease Control and Prevention, Hangzhou, 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Yantao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Daming County Center for Disease Control and Prevention, Handan, 056900, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qinghai</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Liucheng County Center for Disease Control and Prevention, Liuzhou, 545200, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Tingdong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Xiangtan County Center for Disease Control and Prevention, Xiangtan, 411228, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Haiyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Yuhuan County Center for Disease Control and Prevention, Taizhou, 317600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xingliang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Institutes for Food and Drug Control, Beijing, 100050, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Dongyang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Weigang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Yongnian County Center for Disease Control and Prevention, Handan, 056000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Xiangchu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Rongshui Miao Autonomous County Center for Disease Control and Prevention, Liuzhou, 545300, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Liuyifan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Que</LastName><ForeName>Dinghong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>You County Center for Disease Control and Prevention, Zhuzhou, 412315, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhongbing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Longyou County Center for Disease Control and Prevention, Quzhou, 324400, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Laishui County Center for Disease Control and Prevention, Baoding 074100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qingrong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Jiangshan County Center for Disease Control and Prevention, Quzhou, 324100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xinguo</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuliang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hebei Center for Disease Control and Prevention, Shijiazhuang, 050021, China. Electronic address: yuliang_zh@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Gelin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Product Co., Ltd., Wuhan, 430207, China. Electronic address: gelinxu@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>China National Biotec Group Company Limited, National Engineering Technology Research Center for Combined Vaccines, Wuhan, 430207, China. Electronic address: yangxiaoming@sinopharm.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Virol Sin</MedlineTA><NlmUniqueID>101514185</NlmUniqueID><ISSNLinking>1995-820X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022243">Rotavirus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005759" MajorTopicYN="Y">Gastroenteritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012401" MajorTopicYN="Y">Rotavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012400" MajorTopicYN="Y">Rotavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022243" MajorTopicYN="Y">Rotavirus Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Infants</Keyword><Keyword MajorTopicYN="N">Rotavirus gastroenteritis (RVGE)</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35926726</ArticleId><ArticleId IdType="pmc">PMC9583109</ArticleId><ArticleId IdType="doi">10.1016/j.virs.2022.07.011</ArticleId><ArticleId IdType="pii">S1995-820X(22)00135-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chan I.S.F., Bohidar N.R. Exact power and sample size for vaccine efficacy studies. Commu. Stat-Theory Methods. 1998;27:1305&#x2013;1322.</Citation></Reference><Reference><Citation>Chen D., Liu C., Lv H., Shi H., Shang J., Yin Y., Luo P., Luo W. Investigation on rotavirus diarrhea in infants aged two years and below in Yuhan. Prev. Med. 2019;31:628&#x2013;630. (In Chinese)</Citation></Reference><Reference><Citation>Chen H., Li Q., Duan K., Shi C., Zhang D., Dong B., Bai X., Qiao J., Xu G., Yang X., Gao Z., Li F., Lv H., Zhou H., Yan T., Shi H. Molecular epidemiological characteristics of rotavirus VP7 gene in zhengding county of Hebei province, xiangtan county of hunan province and yuhuan city of Zhejiang province, China from 2016 to 2017. Chin J Biologicals. 2021;34:415&#x2013;427. (In Chinese)</Citation></Reference><Reference><Citation>Ciarlet M., Schodel F. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine. RotaTeq. Vaccine. 2009;27(Suppl. 6):G72&#x2013;G81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20006144</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements-Mann M.L., Dudas R., Hoshino Y., Nehring P., Sperber E., Wagner M., Stephens I., Karron R., Deforest A., Kapikian A.Z. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine. 2001;19:4676&#x2013;4684.</Citation><ArticleIdList><ArticleId IdType="pubmed">11535316</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos B., Han H.H., Bouckenooghe A., Debrus S., Gillard P., Ward R., Cheuvart B. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr. Infect. Dis. J. 2009;28:261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">19289978</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhingra M.S., Kundu R., Gupta M., Kanungo S., Ganguly N., Singh M.P., Bhattacharya M.K., Ghosh R., Kumar R., Sur D., Chadha S.M., Saluja T. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1&#x2013;G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine. 2014;32(Suppl. 1):A117&#x2013;A123.</Citation><ArticleIdList><ArticleId IdType="pubmed">25091664</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Z.Y., Wang B., Kilgore P.E., Bresee J.S., Zhang L.J. Sentinel hospital surveillance for rotavirus diarrhea in the People&#x2019;s Republic of China, August 2001&#x2013;July 2003. J&#xa0;Infect Dis. 2005;192(S):S94&#x2013;S99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni P.S., Desai S., Tewari T., Kawade A., Goyal N., Garg B.S., Kumar D., Kanungo S., Kamat V., Kang G., Bavdekar A., Babji S., Juvekar S., Manna B., Dutta S., Angurana R., Dewan D., Dharmadhikari A., Zade J.K., Dhere R.M., Fix A., Power M., Uprety V., Parulekar V., Cho I., Chandola T.R., Kedia V.K., Raut A., Flores J. A&#xa0;randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35:6228&#x2013;6237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5651219</ArticleId><ArticleId IdType="pubmed">28967523</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau Y.L., Nelson E.A., Poon K.H., Chan P.K., Chiu S., Sung R., Leung C.W., Ng D., Ma Y.M., Chan D., Lee T.L., Tang J., Kwan Y.W., Ip P., Ho M., Fung L.W., Tang H., Suryakiran P.V., Han H.H., Bock H., Hong Kong Rotarix Study G. Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial. Vaccine. 2013;31:2253&#x2013;2259.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499605</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R.C., Huang T., Li Y., Luo D., Tao J., Fu B., Si G., Nong Y., Mo Z., Liao X., Luan I., Tang H., Rathi N., Karkada N., Han H.H. Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China. Hum. Vaccines Immunother. 2014;10:11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181005</ArticleId><ArticleId IdType="pubmed">24013441</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., Xu Z., Li D., Zhang Q., Wang H., Duan Z.J. Update on the disease burden and circulating strains of rotavirus in China: a systematic review and meta-analysis. Vaccine. 2014;32:4369&#x2013;4375.</Citation><ArticleIdList><ArticleId IdType="pubmed">24958704</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Li Q., Bai X., Jiang Z., Zhang J., Feng D., Yang B., Dong B., Chen T., Yan T., He S., Yang Kejia, Li F., Mo Z., Wang X., Xu G. Epidemiological investigation on rotavirus diarrhea in infants at ages of less than 2 years in xiangtan county, hunan province and Rongshui county, Guangxi zhaung autonomous region, China. Chin. J. Biologicals. 2020;33:684&#x2013;688. (In Chinese)</Citation></Reference><Reference><Citation>Mo Z., Mo Y., Li M., Tao J., Yang X., Kong J., Wei D., Fu B., Liao X., Chu J., Qiu Y., Hille D.A., Nelson M., Kaplan S.S. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine. 2017;35:5897&#x2013;5904.</Citation><ArticleIdList><ArticleId IdType="pubmed">28935470</ArticleId></ArticleIdList></Reference><Reference><Citation>National Medical Products Administration (NMPA)  Guidelines for grading criteria of adverse events in clinical trials of preventive vaccines. (Registration No. 493) 2005. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20051014010101369.html</Citation></Reference><Reference><Citation>National Medical Products Administration (NMPA)  Guidelines for grading criteria of adverse events in clinical trials of preventive vaccines. (Registration No.102) 2019. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20191231111901460.html</Citation></Reference><Reference><Citation>Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., Lee B.W., Van Doorn L.J., Teoh Y.L., Tang H., Suryakiran P.V., Smolenov I.V., Bock H.L., Han H.H. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine. 2012;30:4552&#x2013;4557.</Citation><ArticleIdList><ArticleId IdType="pubmed">22497874</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesikari T., Karvonen A.V., Majuri J., Zeng S.Q., Pang X.L., Kohberger R., Forrest B.D., Hoshino Y., Chanock R.M., Kapikian A.Z. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J.&#xa0;Infect. Dis. 2006;194:370&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">16826486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.J., Chen L.N., Wang S.M., Zhou H.L., Qiu C., Jiang B., Qiu T.Y., Chen S.L., von Seidlein L., Wang X.Y. Genetic characterization of two G8P[8] rotavirus strains isolated in Guangzhou, China, in 2020/21: evidence of genome reassortment. BMC Infect. Dis. 2022;22:579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9238253</ArticleId><ArticleId IdType="pubmed">35764948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L.P., Zhou S.X., Wang X., Lu Q.B., Shi L.S., Ren X., Zhang H.Y., Wang Y.F., Lin S.H., Zhang C.H., Geng M.J., Zhang X.A., Li J., Zhao S.W., Yi Z.G., Chen X., Yang Z.S., Meng L., Wang X.H., Liu Y.L., Cui A.L., Lai S.J., Liu M.Y., Zhu Y.L., Xu W.B., Chen Y., Wu J.G., Yuan Z.H., Li M.F., Huang L.Y., Li Z.J., Liu W., Fang L.Q., Jing H.Q., Hay S.I., Gao G.F., Yang W.Z., Chinese Centers for Disease Control and Prevention (CDC) Etiology of Diarrhea Surveillance Study Team Etiological, epidemiological, and clinical features of acute diarrhea in China. Nat. Commun. 2021;12:2464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8085116</ArticleId><ArticleId IdType="pubmed">33927201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.Y., Riewpaiboon A., von Seidlein L., Chen X.B., Kilgore P.E., Ma J.C., Qi S.X., Zhang Z.Y., Hao Z.Y., Chen J.C., Xu Z.Y. Potential cost effectiveness of a rotavirus immunization program in rural China. Clin. Infect. Dis. 2009;49:1202&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pubmed">19739973</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral), Annex 3, TRS No 941. 2007. https://www.who.int/publications/m/item/oral-live-attenuated-rotavirus-vaccines-annex-3-trs-no-941</Citation></Reference><Reference><Citation>Wu Z.W., Li Q.L., Zhou H.S., Duan K., Gao Z., Zhang X.J., Jiang Z.J., Hao Z.Y., Jin F., Bai X., Li Q., Xu G.L., Zhao Y.L., Yang X.M. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine: a phase I clinical trial. Hum. Vaccines Immunother. 2021;17:2311&#x2013;2318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189138</ArticleId><ArticleId IdType="pubmed">33545015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Zhang Y., Gao Z., Liu Y., Li Q., Wu Z., Su T., Yang Z., Zhao Y. Monitoring results of rotavirus diarrhea in infants aged 0-24 months in a county of Hebei Province. Pract. Prev. Med. 2020;27:708&#x2013;711.</Citation></Reference><Reference><Citation>Zhang T., Li J., Jiang Y.Z., Xu J.Q., Guan X.H., Wang L.Q., Chen J., Liang Y. Genotype distribution and evolutionary analysis of rotavirus associated with acute diarrhea outpatients in Hubei, China, 2013-2016. Virol. Sin. 2022;37:503&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9437618</ArticleId><ArticleId IdType="pubmed">35643410</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>